TV presenter Vanessa Feltz has expressed regret over her past decision to undergo gastric bypass surgery, stating that she would not have proceeded with the procedure had she known about the weight loss drug, Ozempic. The medication, which has gained popularity among celebrities for its effectiveness in aiding weight loss, was approved for medical use in the United States in 2017.
Feltz, who opted for a gastric band in 2010 followed by gastric bypass surgery in 2019, acknowledged that she missed out on the Ozempic trend. In an interview with The Times, the 62-year-old openly admitted that she would have opted for Ozempic instead of surgery, referring to the drug as “fabulous.” She expressed disappointment in pre-dating the availability of Ozempic, stating, “I would not have had the surgery.”
The TV and radio host candidly shared that she would have been willing to use Ozempic for the rest of her life, had she known about it earlier. Despite not using the drug herself, Feltz noted that many public figures who have successfully shed weight are believed to have used Ozempic. She emphasised the appeal of being thin, even amidst uncertainties about the drug’s long-term effects.
Feltz’s comments come in the wake of a recent health scare where she was hospitalised due to severe pain caused by a kidney stone. Following the discovery of the 5mm-long stone, Feltz underwent a procedure to have it removed, describing the experience as more agonising than childbirth.
The growing demand for weight-loss injections such as Wegovy has raised concerns among medical professionals and experts. Calls have been made for Health Secretary Wes Streeting to review the impact of these drugs on NHS services, with the Obesity Health Alliance highlighting challenges faced by specialist weight-management services in meeting the surge in demand. Streeting has signalled the potential use of weight-loss injections for individuals facing unemployment due to obesity issues, as the government commits a substantial investment of £279 million into trialling such interventions in the UK’s life sciences sector.
The ongoing debate surrounding weight loss methods and their implications on public health underscores the evolving landscape of healthcare interventions aimed at combatting obesity and related health concerns. Vanessa Feltz’s personal reflections on her weight loss journey and the emergence of alternative treatments like Ozempic offer insight into the complex decisions individuals face when addressing weight management issues in today’s society.